Adjuvant Therapy
Addition of nivolumab to neoadjuvant chemotherapy confers benefit in resectable NSCLC
The addition of nivolumab to neoadjuvant chemotherapy led to a significantly higher pathologic complete response rate among patients with resectable non-small cell lung cancer, according to results of a randomized phase 3 trial.
Adjuvant pembrolizumab extends DFS in renal cell carcinoma
Adjuvant therapy does not extend survival in high-risk endometrial cancer
Postoperative systemic or radiation therapy did not extend survival for women with high-risk stage I endometrial cancer, according to results presented at the virtual Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
Chronic adverse events more common than thought after adjuvant immunotherapy for melanoma
Chronic immune-related adverse events appeared more common than previously thought among patients with stage III to stage IV melanoma who received adjuvant anti-PD-1 therapy, according to study results published in JAMA Oncology.
Adjuvant gefitinib extends DFS, not OS vs. chemotherapy in NSCLC subset
Adjuvant gefitinib may be a reasonable alternative to standard-of-care chemotherapy for patients with EGFR-positive stage II or stage IIIA non-small cell lung cancer, according to study results published in Journal of Clinical Oncology.
Nivolumab may be ‘new standard’ in esophageal, gastroesophageal junction cancers
Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.
Adjuvant nivolumab extends DFS in urothelial carcinoma subset
Adjuvant nivolumab significantly prolonged DFS compared with placebo for patients with high-risk, muscle-invasive urothelial carcinoma, according to topline data released by the agent’s manufacturer.
VIDEO: Virtual cancer meetings successful, but data discussion difficult
In this video, Roy S. Herbst, MD, PhD, discussed how the 21st annual International Lung Cancer Congress went virtual this year.
FDA grants breakthrough therapy designation to Tagrisso for lung cancer subset
The FDA granted breakthrough therapy designation to osimertinib for adjuvant treatment of certain patients with early-stage non-small cell lung cancer, according to the agent’s manufacturer.
Adjuvant immunotherapy extends OS for certain patients with stage III melanoma
Adjuvant immunotherapy conferred a significant OS benefit among patients with resected stage IIIC melanoma, according to study results presented at American Association for Cancer Research Virtual Annual Meeting II.